Prevalence, Patterns, and Costs of Chinese Medicine Use Among Prostate Cancer Patients: A Population-Based Study in Taiwan

The prevalence and costs of insurance-covered CM among prostate cancer patients were low. Most prostate cancer patients did not use insurance-covered CM. The majority of CM users also used WM. CM appeared to play a complementary rather than an alternative role.